skip to primary navigationskip to content
 

11.12.15 NICE approves olaparib (Lynparza) for use by the NHS

last modified Dec 13, 2015 05:36 PM
NICE has approved olaparib for use by the NHS for certain ovarian cancer patients, bringing the drug to around 400 women per year in England and Wales
11.12.15 NICE approves olaparib (Lynparza) for use by the NHS

Chemical structure of olaparib (Lynparza)

The National Institute for Health and Care Excellence (NICE) has approved the drug olaparib for use on the NHS. Women with ovarian cancer who carry faulty versions of the BRCA1 and 2 genes that have already responded to chemotherapy will be eligible for the drug.  Clinical trials showed that the drug extends the lives of patients by an average of seven months; some women are still alive after several years.  

Patients in England and Wales have had to wait a year longer to access the drug than those in Europe and the USA, while officials wrangled over the price - Lynparza now costs £3550 per month. The initial rounds of treatment will be covered by the NHS, but women who remain on treatment after 15 months will then have the drug paid for by the manufacturer.  Around 400 women per year are expected to be eligible for the treatment.

The Gurdon Institute's Prof. Steve Jackson, University of Cambridge and Cancer Research UK Professor of Biology, who played a leading role in developing olaparib, welcomed NICE's decision.

"It is wonderful to learn that olaparib, a drug that was developed as a result of British science and innovation, is finally being made available through the NHS to certain ovarian cancer patients," he said.

"Times like this, when a new medicine becomes available, are important - most of all for the patients themselves, but also for everyone involved in cancer research, all the way from fundraisers to research scientists and clinicians."

"This news also increases my optimism about potential applications for olaparib in other cancers, as well as for the prospects of additional new anti-cancer medicines that are being developed through the joint efforts of charities, academic institutions and companies."

Clinical trials are in progress to test the use of Lynparza against several other types of cancer including gastric, prostate and breast.

 

 

Watch Jackson describe the science behind olaparib, which works by inhibiting the enzyme PARP in cells that are dependent on PARP to repair DNA damage.

More about current research in the Jackson lab.

Studying development to understand disease

The Gurdon Institute is funded by Wellcome and Cancer Research UK to study the biology of development, and how normal growth and maintenance go wrong in cancer and other diseases.

combinedLogo x3 trans2018

 

Share this

Mutations in thyroid hormone receptor α1 cause premature neurogenesis and progenitor cell depletion in human cortical development

Neural stem cell temporal patterning and brain tumour growth rely on oxidative phosphorylation

Testing the role of SOX15 in human primordial germ cell fate

Genome architecture and stability in the Saccharomyces cerevisiae knockout collection

Long noncoding RNAs are involved in multiple immunological pathways in response to vaccination

Defining the Identity and Dynamics of Adult Gastric Isthmus Stem Cells

Interaction of Sox2 with RNA binding proteins in mouse embryonic stem cells

Disease modelling in human organoids

The role of integrins in Drosophila egg chamber morphogenesis

Tracing the cellular dynamics of sebaceous gland development in normal and perturbed states

Neural stem cell dynamics: the development of brain tumours

Liver organoids: from basic research to therapeutic applications

NSUN2 introduces 5-methylcytosines in mammalian mitochondrial tRNAs

The roles of DNA, RNA and histone methylation in ageing and cancer

Separating Golgi proteins from cis to trans reveals underlying properties of cisternal localization

Sequencing cell-type-specific transcriptomes with SLAM-ITseq

Mature sperm small-RNA profile in the sparrow: implications for transgenerational effects of age on fitness

Single-cell transcriptome analyses reveal novel targets modulating cardiac neovascularization by resident endothelial cells following myocardial infarction

Derivation and maintenance of mouse haploid embryonic stem cells

Establishment of porcine and human expanded potential stem cells

Adapting machine-learning algorithms to design gene circuits

Link to full list on PubMed